These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 30390687)
1. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Śmiech A; Ślaska B; Łopuszyński W; Jasik A; Bochyńska D; Dąbrowski R Acta Vet Scand; 2018 Nov; 60(1):70. PubMed ID: 30390687 [TBL] [Abstract][Full Text] [Related]
2. Epidemiological Study of Canine Mast Cell Tumours According to the Histological Malignancy Grade. Śmiech A; Ślaska B; Łopuszyński W; Jasik A; Szczepanik M; Wilkołek P Pol J Vet Sci; 2017 Sep; 20(3):455-465. PubMed ID: 29166281 [TBL] [Abstract][Full Text] [Related]
3. Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors. Martins AL; Carvalho FF; Mesquita JR; Gärtner F; Amorim I Open Vet J; 2021; 11(4):619-634. PubMed ID: 35070857 [TBL] [Abstract][Full Text] [Related]
4. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours. Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627 [TBL] [Abstract][Full Text] [Related]
6. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). Stefanello D; Buracco P; Sabattini S; Finotello R; Giudice C; Grieco V; Iussich S; Tursi M; Scase T; Di Palma S; Bettini G; Ferrari R; Martano M; Gattino F; Marrington M; Mazzola M; Elisabetta Vasconi M; Annoni M; Marconato L J Am Vet Med Assoc; 2015 Apr; 246(7):765-9. PubMed ID: 25794126 [TBL] [Abstract][Full Text] [Related]
7. Association of breed and histopathological grade in canine mast cell tumours. Mochizuki H; Motsinger-Reif A; Bettini C; Moroff S; Breen M Vet Comp Oncol; 2017 Sep; 15(3):829-839. PubMed ID: 27198171 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of pre-treatment biopsy for grading cutaneous mast cell tumours in dogs. Shaw T; Kudnig ST; Firestone SM Vet Comp Oncol; 2018 Jun; 16(2):214-219. PubMed ID: 28857446 [TBL] [Abstract][Full Text] [Related]
9. Histologic grading of canine mast cell tumor: is 2 better than 3? Sabattini S; Scarpa F; Berlato D; Bettini G Vet Pathol; 2015 Jan; 52(1):70-3. PubMed ID: 24513799 [TBL] [Abstract][Full Text] [Related]
10. Cytological grading of canine cutaneous mast cell tumours. Scarpa F; Sabattini S; Bettini G Vet Comp Oncol; 2016 Sep; 14(3):245-51. PubMed ID: 24717019 [TBL] [Abstract][Full Text] [Related]
11. Patient and tumour factors influencing canine mast cell tumour histological grade and mitotic index. Reynolds BD; Thomson MJ; O'Connell K; Morgan EJ; Gummow B Vet Comp Oncol; 2019 Sep; 17(3):338-344. PubMed ID: 30891882 [TBL] [Abstract][Full Text] [Related]
12. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers. Gil da Costa RM; Matos E; Rema A; Lopes C; Pires MA; Gärtner F BMC Vet Res; 2007 Aug; 3():19. PubMed ID: 17711582 [TBL] [Abstract][Full Text] [Related]
13. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis. Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539 [TBL] [Abstract][Full Text] [Related]
14. Histopathological features of subcutaneous and cutaneous mast cell tumors in dogs. Minnoye S; De Vos S; Beck S; Duchateau L; Hubers M; David S; Fortrie R; de Rooster H Acta Vet Scand; 2024 Oct; 66(1):53. PubMed ID: 39354622 [TBL] [Abstract][Full Text] [Related]
15. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. Kiupel M; Webster JD; Miller RA; Kaneene JB J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909 [TBL] [Abstract][Full Text] [Related]
16. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours. Moore AS; Frimberger AE; Taylor D; Sullivan N Vet Comp Oncol; 2020 Sep; 18(3):402-408. PubMed ID: 31916687 [TBL] [Abstract][Full Text] [Related]
17. Occurrence and Distribution of Canine Cutaneous Mast Cell Tumour Characteristics Among Predisposed Breeds. Śmiech A; Łopuszyński W; Ślaska B; Bulak K; Jasik A J Vet Res; 2019 Mar; 63(1):141-148. PubMed ID: 30989146 [TBL] [Abstract][Full Text] [Related]
18. Breed related odds ratio and anatomic distribution of canine mast cell tumours in Austria. Retrospective study of cases in the years 2000-2010. Leidinger EF; Freeman K; Kirtz G; Hooijberg EH; Sick K Tierarztl Prax Ausg K Kleintiere Heimtiere; 2014; 42(6):367-73. PubMed ID: 25418504 [TBL] [Abstract][Full Text] [Related]
19. Extensive staging has no prognostic value in dogs with low-risk mast cell tumours. Fejös C; Troedson K; Ignatenko N; Zablotski Y; Hirschberger J Vet Comp Oncol; 2022 Mar; 20(1):265-275. PubMed ID: 34564910 [TBL] [Abstract][Full Text] [Related]
20. High lysyl oxidase expression is an indicator of poor prognosis in dogs with cutaneous mast cell tumours. Joselevitch JA; Vargas THM; Pulz LH; Cadrobbi KG; Huete GC; Nishiya AT; Kleeb SR; Xavier JG; Strefezzi RF Vet Comp Oncol; 2023 Sep; 21(3):401-405. PubMed ID: 37186079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]